[go: up one dir, main page]

PE20150189A1 - Formas de administracion farmaceuticas que comprenden 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)fenil]-1,3-oxazolidin-5-il}metil)-2-tiofencarboxamida - Google Patents

Formas de administracion farmaceuticas que comprenden 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)fenil]-1,3-oxazolidin-5-il}metil)-2-tiofencarboxamida

Info

Publication number
PE20150189A1
PE20150189A1 PE2014002579A PE2014002579A PE20150189A1 PE 20150189 A1 PE20150189 A1 PE 20150189A1 PE 2014002579 A PE2014002579 A PE 2014002579A PE 2014002579 A PE2014002579 A PE 2014002579A PE 20150189 A1 PE20150189 A1 PE 20150189A1
Authority
PE
Peru
Prior art keywords
oxo
oxazolidin
morpholinyl
chloro
phenyl
Prior art date
Application number
PE2014002579A
Other languages
English (en)
Inventor
Klaus Benke
Heike Neumann
Wolfgang Muck
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48782297&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20150189(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of PE20150189A1 publication Critical patent/PE20150189A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Referida a una forma de administracion farmaceutica administrable por via oral solida que comprende al compuesto 5-cloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morfolinil)fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida (rivaroxaban, compuesto activo I) caracterizada porque se libera rapidamente una cantidad parcial del compuesto activo (I) y se libera una cantidad parcial de una forma controlada (modificada, retardada, pospuesta), y a procedimientos para su preparacion
PE2014002579A 2012-07-03 2013-06-28 Formas de administracion farmaceuticas que comprenden 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)fenil]-1,3-oxazolidin-5-il}metil)-2-tiofencarboxamida PE20150189A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12174797 2012-07-03

Publications (1)

Publication Number Publication Date
PE20150189A1 true PE20150189A1 (es) 2015-01-31

Family

ID=48782297

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014002579A PE20150189A1 (es) 2012-07-03 2013-06-28 Formas de administracion farmaceuticas que comprenden 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)fenil]-1,3-oxazolidin-5-il}metil)-2-tiofencarboxamida

Country Status (33)

Country Link
US (2) US20150125527A1 (es)
EP (1) EP2869814B1 (es)
JP (1) JP6166781B2 (es)
KR (1) KR20150027284A (es)
CN (1) CN104582684A (es)
AP (1) AP3756A (es)
AR (1) AR091621A1 (es)
AU (1) AU2013286068A1 (es)
BR (1) BR112015000043A2 (es)
CA (1) CA2878123A1 (es)
CL (1) CL2015000002A1 (es)
CO (1) CO7240379A2 (es)
CR (1) CR20150001A (es)
CU (1) CU20140152A7 (es)
DO (1) DOP2015000001A (es)
EA (1) EA025016B1 (es)
EC (1) ECSP14033581A (es)
ES (1) ES2574627T3 (es)
GT (1) GT201400306A (es)
HK (1) HK1209635A1 (es)
IL (1) IL236455A0 (es)
IN (1) IN2014DN11066A (es)
MA (1) MA37721B1 (es)
MX (1) MX2015000053A (es)
NZ (1) NZ703733A (es)
PE (1) PE20150189A1 (es)
PH (1) PH12014502833A1 (es)
SG (1) SG11201408420YA (es)
TN (1) TN2014000541A1 (es)
TW (1) TW201414508A (es)
UY (1) UY34856A (es)
WO (1) WO2014005934A1 (es)
ZA (1) ZA201500759B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008059206A1 (de) * 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
CA3010726A1 (en) * 2016-02-23 2017-08-31 Morgandane Scientific, LLC Method of treating patients coadministered a factor xa inhibitor and verapamil
CN107823166A (zh) * 2016-09-21 2018-03-23 齐鲁制药有限公司 一种利伐沙班片的制备方法
JP2021532113A (ja) * 2018-07-24 2021-11-25 バイエル・アクチエンゲゼルシヤフト 経口投与可能であり、放出を修飾した薬学的投薬形態
US20210283046A1 (en) * 2018-07-24 2021-09-16 Bayer Aktiengesellschaft Pharmaceutical dosage form which can be administered orally and has modified release
US10722486B2 (en) 2018-08-13 2020-07-28 Morgandane Scientific, LLC Method of treating patients with a factor Xa inhibitor, aspirin, and verapamil
JP7641098B2 (ja) * 2019-08-30 2025-03-06 日本ジェネリック株式会社 リバーロキサバン含有錠剤
JP7465157B2 (ja) * 2020-06-15 2024-04-10 沢井製薬株式会社 リバーロキサバン含有口腔内崩壊錠の製造方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
NZ206600A (en) 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US5160744A (en) 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US6919373B1 (en) * 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
DE19747261A1 (de) 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
WO1999062496A1 (en) * 1998-06-03 1999-12-09 Alza Corporation Methods and devices for providing prolonged drug therapy
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
US8092831B2 (en) * 2002-11-08 2012-01-10 Andrx Pharmaceuticals, Llc Antihistamine and decongestant system
AR046811A1 (es) * 2003-09-02 2005-12-28 Imran Ahmed Formas de dosificacion oral de ziprasidona de liberacion sostenida
DE10355461A1 (de) * 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
WO2010003641A1 (en) * 2008-07-08 2010-01-14 Ratiopharm Gmbh Pharmaceutical compositions comprising 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
GB201003734D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
BR112012032816A2 (pt) * 2010-06-22 2016-11-08 Twi Pharmaceuticals composição farmacêutica de liberação controlada, e, métodos para reduzir o efeito alimentar de uma composição de liberação controlada, reduzir o período de tempo necessário para que seja alcançado um estado estável para a metformina, para aperfeiçoar a biodisponibilidade de uma forma de dosagem de liberação controlada de matriz

Also Published As

Publication number Publication date
MA37721A1 (fr) 2016-05-31
DOP2015000001A (es) 2015-07-15
CN104582684A (zh) 2015-04-29
CA2878123A1 (en) 2014-01-09
TW201414508A (zh) 2014-04-16
CO7240379A2 (es) 2015-04-17
PH12014502833A1 (en) 2015-02-02
US20140010876A1 (en) 2014-01-09
UY34856A (es) 2013-12-31
AP2015008208A0 (en) 2015-01-31
CU20140152A7 (es) 2015-10-27
MA37721B1 (fr) 2016-12-30
MX2015000053A (es) 2015-04-10
ZA201500759B (en) 2017-11-29
EP2869814A1 (de) 2015-05-13
KR20150027284A (ko) 2015-03-11
JP6166781B2 (ja) 2017-07-19
SG11201408420YA (en) 2015-01-29
EA201590142A1 (ru) 2015-06-30
HK1209635A1 (en) 2016-04-08
GT201400306A (es) 2015-08-25
IL236455A0 (en) 2015-02-26
EA025016B1 (ru) 2016-11-30
AP3756A (en) 2016-07-31
EP2869814B1 (de) 2016-04-06
ECSP14033581A (es) 2015-12-31
NZ703733A (en) 2016-12-23
WO2014005934A1 (de) 2014-01-09
ES2574627T3 (es) 2016-06-21
AR091621A1 (es) 2015-02-18
BR112015000043A2 (pt) 2017-06-27
TN2014000541A1 (en) 2016-03-30
JP2015521648A (ja) 2015-07-30
US20150125527A1 (en) 2015-05-07
CL2015000002A1 (es) 2015-05-29
AU2013286068A1 (en) 2015-01-29
IN2014DN11066A (es) 2015-09-25
CR20150001A (es) 2015-02-06

Similar Documents

Publication Publication Date Title
PE20150189A1 (es) Formas de administracion farmaceuticas que comprenden 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)fenil]-1,3-oxazolidin-5-il}metil)-2-tiofencarboxamida
ECSP088339A (es) Formas de presentación farmacéutica sólidas de administración oral con liberación rápida de principio activo
BRPI0519376A2 (pt) formas de administraÇço farmacÊuticas sàlidas, aplicÁveis por via oral, contendo rivaroxaban com liberaÇço modificada
ECSP066584A (es) Procedimiento para la producción de una composición farmacéutica sólida de administración oral
ATE545645T1 (de) Neue cokristall-verbindung von rivaroxaban und malonsäure
DK1987026T3 (da) Aminoacyl-prodrugderivater og lægemidler til behandling af thromboemboliske sygdomme
WO2012080184A3 (de) Flüssige, oral applizierbare pharmazeutische zusammensetzungen enthaltend 5-chlor-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
PH12015501625A1 (en) Aldehyde derivative of substitute oxazolidinones
IL250168A0 (en) Crystalline form of 5 – chloro –n ( { (5s) – 2 – oxo – 3 – [ 4 – ( 5,6 – dihydro – 4h – [ 1,2,4 ] triazin-1-yl) phenyl] – 1, 3-oxazolidine-5-yl}methyl)thiophene-2-an innovative carboxamide and pharmaceutical preparations containing it
CU20080051A7 (es) Nueva forma polimórfica y la forma amorfa de 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofenocarboxamida
NO20081982L (no) Faste, oralt administrerbare farmasoytiske doseringsformer med rask frigivelse av aktiv forbindelse
DOP2004001034A (es) Procedimiento para la preparacion de una composicion farmaceutica solida administrable oralmente que comprende 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida en forma hidrofilizada
CU23673B7 (es) Formas de dosificacion farmacéutica sólidas administrables por vía oral con liberación modificada

Legal Events

Date Code Title Description
FD Application declared void or lapsed